researchers recommended that people who received it get a second booster dose with an mRNA vaccine such as Moderna and Pfizer. According to the published results, there were 129 coronavirus ...

Concerns about the COVID-19 shots have increased after a report that drug maker Moderna failed to inform the U.S. government ...

Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.

Erica Denhoff / Icon Sportswire via Getty Images Moderna received a $590 million award from the U.S. government to speed development of a vaccine that could be used to fight bird flu. The biotech ...

The biotech, renowned for its pioneering development of vaccines ... could be the booster shot the stock needs to generate a rebound. It's been more than four years since Moderna rose to ...

The U.S. government has handed Moderna almost $600 million to accelerate its work on various bird flu vaccines as well as work on mRNA vaccines for other influenza strains with pandemic potential.

Under the resulting agreement, 17 participating countries can access Moderna's mRNA COVID-19 vaccine for up to four years. "This agreement presents an opportunity for Moderna to support and ...

Moderna stock has been under pressure amid declining sales of its COVID-19 vaccine. The company projects ... in clinical trials that could be the booster shot the stock needs to generate a rebound.